New York-Last week, the Food and Drug Administration granted Siemens Healthineers emergency use authorization for its Advia Centaur SARS-CoV-2 IgG or sCOVG test.
Chemiluminescence immunoassay is designed for qualitative and semi-quantitative detection of immunoglobulin G or IgG against SARS-CoV-2 in serum and plasma. The test is run on Siemens’ Advia Centaur XP, Advia Centaur XPT and Advia Centaur CP immunoassay systems.
According to the FDA, this test can be used by any CLIA-accredited laboratory to perform moderate or highly complex tests.
In March of this year, the SARS-CoV-2 IgG immunoassay run by Siemens AG, headquartered in Erlangen, Germany, on its Atellica IM analyzer, received an EUA from the FDA.
Privacy Policy. Terms and conditions. Copyright © 2021 GenomeWeb, a business unit of Crain Communications. all rights reserved.
Post time: Jun-28-2021